{"ticker": {"uuid": "15823083-e764-4961-9256-7dc0bb1a91e4", "symbol": "TNGX", "name": "Tango Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating", "summary": "Mizuho has increased its price target for Tango Therapeutics (NASDAQ: TNGX) to $40, up from the previous $36, while maintaining an Outperform rating. This adjustment suggests a positive outlook on the company's future performance and stock valuation.", "url": "https://www.moomoo.com/news/post/73141654/mizuho-raises-price-target-on-tango-therapeutics-to-40-from", "source_name": "Moomoo", "published_at": "2026-07-18T05:09:30", "published_display": "18 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Maintained by Mizuho -- Price Target Raised to $40.00", "summary": "Mizuho has maintained an \"Outperform\" rating for Tango Therapeutics (TNGX) and increased its price target to $40.00, reflecting optimism about the company's growth in cancer therapies. Despite the positive analyst sentiment, GuruFocus indicates that TNGX is significantly overvalu", "url": "https://www.gurufocus.com/news/8965294/tngx-maintained-by-mizuho-price-target-raised-to-4000", "source_name": "GuruFocus", "published_at": "2026-07-17T19:41:22", "published_display": "17 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho raises Tango Therapeutics stock price target on combo data", "summary": "Mizuho has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $40 from $36, maintaining an Outperform rating, based on promising new data for its drug combinations in pancreatic cancer. This comes amidst recent positive analyst revisions and a significant stock of", "url": "https://www.investing.com/news/analyst-ratings/mizuho-raises-tango-therapeutics-stock-price-target-on-combo-data-93CH-4798117", "source_name": "Investing.com", "published_at": "2026-07-17T11:40:32", "published_display": "17 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46", "summary": "J.P. Morgan has initiated coverage on Tango Therapeutics (TNGX.US) with a 'Buy' rating. The investment bank has also set a target price of $46 for the company's stock.", "url": "https://www.moomoo.com/news/post/73000102/jp-morgan-initiates-tango-therapeutics-tngxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-16T00:40:11", "published_display": "16 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYzNHX2ZxUVlmUW5TNXlwS1FTMDRTUy1IdFR5MVVqN201SUZITVFwVUFiekdxOHNDdFR3ZElBeTdpbEtZZGhKSXQyOEYwQjBTd0VjVERDWXNudTRocEJTR3Z0enJJOXZFbzRiNklzNHl2VmdfMm1jRXVuZ3VfZEpudUdxYmw1Y0FrQlE4bFhhQUdqTGM4UmpIeDh6YWx4WjBkdU53UW44VDk?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:54+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates Tango Therapeutics stock at Overweight", "summary": "JPMorgan initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with an Overweight rating and a price target of $46.00, citing progress with its lead PRMT5 inhibitor vopimetostat and promising combination trial data. The company has seen significant stock growth, streamlined", "url": "https://m.investing.com/news/analyst-ratings/jpmorgan-initiates-tango-therapeutics-stock-at-overweight-93CH-4792323?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-15T12:39:32", "published_display": "15 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.com", "summary": "JPMorgan initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with an Overweight rating and a $46.00 price target, despite the stock's significant surge and being considered overvalued by InvestingPro analysis. The firm highlighted Tango's progress with its lead PRMT5 inhi", "url": "https://ng.investing.com/news/stock-market-news/jpmorgan-initiates-tango-therapeutics-stock-at-overweight-93CH-2599958", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T12:11:19", "published_display": "15 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Initiates Coverage On JP Morgan -- Rating Set to Overweight", "summary": "JP Morgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and a price target of $46.00. Despite this positive analyst recommendation, GuruFocus indicates that TNGX is significantly overvalued by 202.9%, with a GF Value of $9.79 against a current trad", "url": "https://www.gurufocus.com/news/8959689/tngx-initiates-coverage-on-jp-morgan-rating-set-to-overweight?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T12:11:19", "published_display": "15 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Initiates Coverage on Tango Therapeutics With Overweight Rating, $46 Price Target", "summary": "JPMorgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and set a price target of $46. This positive outlook follows several recent developments for Tango Therapeutics, including its inclusion in various Russell indices. The company specializes in d", "url": "https://www.marketscreener.com/news/jpmorgan-initiates-coverage-on-tango-therapeutics-with-overweight-rating-46-price-target-ce7f5eddd080fe23", "source_name": "www.marketscreener.com", "published_at": "2026-07-15T07:25:00", "published_display": "15 Jul 2026 07:25", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Inc (TNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Tango Therapeutics Inc (TNGX), detailing its current price momentum, support and resistance levels, and performance across various technical indicators and moving averages. As of July 15, 2026, TNGX has a price momentum score of 4.21,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tngx/technical", "source_name": "TradingKey", "published_at": "2026-07-14T00:11:34", "published_display": "14 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions?", "summary": "Tango Therapeutics (TNGX) was recently reclassified into several Russell growth indices, moving out of value and microcap segments. This shift frames TNGX as a high-growth, high-risk biotechnology narrative, potentially attracting growth-oriented institutional investors. The comp", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/does-tango-therapeutics-tngx-russell-growth-shift-reveal-its", "source_name": "Simply Wall Street", "published_at": "2026-07-09T09:10:19", "published_display": "09 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 \u2014 But Analysts Still See Massive Upside", "summary": "Tango Therapeutics (TNGX) stock crashed 20% after reporting $0 revenue in Q1, missing Wall Street expectations. Despite this, several analysts like Leerink, Mizuho, and Wedbush raised their price targets and maintained \"Outperform\" ratings, citing factors like upcoming pancreatic", "url": "https://stocktwits.com/news-articles/markets/equity/tngx-stock-worst-day-19-months-after-0-revenue-q1-price-target-double/cZXmP6LRek5", "source_name": "Stocktwits", "published_at": "2026-07-07T10:43:54", "published_display": "07 Jul 2026 10:43", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tango Therapeutics (TNGX) Fully Valued On Russell Index Rebalancing?", "summary": "Tango Therapeutics (TNGX) has experienced significant share price growth, up 48.07% over the past month and 235.27% year-to-date, due to its inclusion in Russell growth benchmarks. Despite a high Price-to-Book multiple of 11.1x, suggesting overvaluation compared to the industry a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/is-tango-therapeutics-tngx-fully-valued-on-russell-index-reb", "source_name": "Simply Wall Street", "published_at": "2026-07-07T09:43:54", "published_display": "07 Jul 2026 09:43", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics president Crystal Adam sells $798,908 in stock", "summary": "Crystal Adam, President of Research & Development at Tango Therapeutics, sold 27,000 shares of company common stock for $798,908 after exercising stock options. The transactions were conducted under a pre-arranged trading plan, with shares sold in two blocks at weighted average p", "url": "https://www.investing.com/news/insider-trading-news/tango-therapeutics-president-crystal-adam-sells-798908-in-stock-93CH-4774754", "source_name": "Investing.com", "published_at": "2026-07-03T08:39:38", "published_display": "03 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tango Therapeutics Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing by Tango Therapeutics Inc., dated July 2. The filing indicates insider trading activity for the company, symbolized as TNGX, which saw a 1.63% increase. The brief announcement provides no further details about the nature of the transaction.", "url": "https://ng.investing.com/news/stock-market-news/form-4-tango-therapeutics-inc-for-2-july-93CH-2585450", "source_name": "Investing.com Nigeria", "published_at": "2026-07-03T00:36:00", "published_display": "03 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares", "summary": "Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised stock options for 27,000 shares at $5.20 per share and subsequently sold all 27,000 shares in open-market transactions. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred at weighte", "url": "https://www.stocktitan.net/sec-filings/TNGX/form-4-tango-therapeutics-inc-insider-trading-activity-f966c52e540d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:40:08", "published_display": "02 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tango Therapeutics, Inc. \u2013 NASDAQ:TNGX", "summary": "This article focuses on the \"Price to book forward\" metric for Tango Therapeutics, Inc. (NASDAQ:TNGX). It appears to be a financial data snippet from TradingView, providing an overview of the company's financial information within their platform. The content primarily shows the n", "url": "https://www.tradingview.com/symbols/NASDAQ-TNGX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T22:40:08", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Rides a New Precision Oncology Trend in 2026", "summary": "Tango Therapeutics is a key player in precision oncology, focusing on MTAP-deleted cancers with therapies like vopimetostat (TNG462) and TNG456. The company is using a synthetic-lethality approach and combination therapies, particularly for pancreatic, lung, and brain tumors, and", "url": "https://sg.finance.yahoo.com/news/tango-therapeutics-rides-precision-oncology-145000365.html", "source_name": "Market source", "published_at": "2026-07-02T14:50:00", "published_display": "02 Jul 2026 14:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?", "summary": "Tango Therapeutics (TNGX) has seen a dramatic rally in 2026 due to promising clinical progress with its drug vopimetostat, particularly for MTAP-deleted, RAS-mutant pancreatic cancer. Despite this, the company faces risks as it is still clinical-stage with no product revenues and", "url": "https://www.tradingview.com/news/zacks:87a242557094b:0-is-tngx-stock-still-worth-buying-after-its-huge-rally-in-2026/", "source_name": "TradingView", "published_at": "2026-07-02T14:39:59", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts", "summary": "Tango Therapeutics (TNGX) is entering a crucial period, with its stock outlook primarily tied to the success of vopimetostat and key clinical updates expected in 2026. The company's strategy focuses on MTAP-deleted cancers with a narrowed pipeline, leading to higher concentration", "url": "https://www.tradingview.com/news/zacks:59da0a0ee094b:0-tngx-stock-outlook-hinges-on-vopimetostat-and-key-2026-catalysts/", "source_name": "TradingView", "published_at": "2026-07-02T14:39:59", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Enters Russell Growth Indexes and Adds Biopharma Veteran Azelby to Board", "summary": "Tango Therapeutics (TNGX) has been included in several Russell Growth benchmarks and simultaneously removed from Value and Microcap indexes in late June 2026, signaling a market perception shift towards it as a high-growth, high-risk biotech. Concurrently, the company appointed b", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-enters-russell-growth-indexes-and-ad", "source_name": "Simply Wall Street", "published_at": "2026-07-01T05:40:41", "published_display": "01 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. This news comes alongside other index adjustments for the company, including being dropped from several ", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-added-to-russell-2500-growth-benchmark-ce7f5fdfdd89fe22", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:39:24", "published_display": "29 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 2000 Growth Benchmark. This news comes alongside several other announcements regarding the company's inclusion and exclusion from various Russell indices, including being dropped from the Russell Small Cap Co", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-added-to-russell-2000-growth-benchmark-ce7f5fded188f12c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:12:16", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM:TNGX) has been removed from the Russell Small Cap Comp Value Benchmark. This decision by S&P Capital IQ was announced on June 29, 2026, at 06:16 am EDT. Concurrently, the company was also added to the Russell 2000 Growth Benchmark and Russell 30", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8aff27", "source_name": "marketscreener.com", "published_at": "2026-06-29T10:12:16", "published_display": "29 Jun 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000 Growth Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 3000 Growth Benchmark, as announced on June 28, 2026. This inclusion is part of several recent index adjustments, which also saw the company added to the Russell 2500 Growth Benchmark and dropped from other b", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-added-to-russell-3000-growth-benchmark-ce7f5fdcd188f421", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:10:24", "published_display": "29 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Could Be 64% Below Fair Value As It Adds Robert Azelby", "summary": "Tango Therapeutics (TNGX) recently appointed Robert Azelby to its Board of Directors, as it advances its investigational PRMT5 inhibitor vopimetostat. The company's share price has shown strong momentum, with significant returns over the last year. Simply Wall St's DCF model esti", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-could-be-64-below-fair-value-as-it-a", "source_name": "Simply Wall Street", "published_at": "2026-06-29T06:39:25", "published_display": "29 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been removed from the Russell 2500 Value Benchmark, as reported by S&P Capital IQ on June 28, 2026. This exclusion is part of several benchmark adjustments for the company around the same date, including additions to growth benchmarks", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-dropped-from-russell-2500-value-benchmark-ce7f5fded880f222", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T21:10:00", "published_display": "28 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Upgrades Tango Therapeutics to Buy From Hold, Price Target is $27", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jefferies-upgrades-tango-therapeutics-buy-111313317.html", "source_name": "MT Newswires", "published_at": "2026-06-26T11:13:13+00:00", "published_display": "26 Jun 2026 11:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Tango Therapeutics (TNGX) receives RSUs and stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxORFRYRUIwRUlRQkxoSmljd08tbGIxb3d0M1ZaQ1NLSHgtUmJlYUF0RW1fcGFSODlPYWdQV0xma3ZKbGFYVWZSQjVEeEdzWmtBVWxSbmc5ZGZyaE5jV0pUdW9rdWxNZGxSb0hsdTlTZ3Y4SGdXMHFtRnN0LVBDak4xODBtMnlRbzdsaWtYWi04N0QxQmUzMHZMNWNfelc5dzUxVENSQjZVT2xNdXN3X0NYODFtV3Ruc1k?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Appoints Robert Azelby to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tango-therapeutics-appoints-robert-azelby-200500260.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T20:05:00+00:00", "published_display": "22 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX (Nasdaq: TNGX) affiliate files Form 144 to sell 3.5M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRVdPWDdVNlh3RVBnM2dmbjBLWlVxRXJYeWQtbFh3ZUJtUmpwRk5rQndGN0hPZEM1SVNzeTJVLXhyTEliYTRtYlNuZ0pKNWdtZmcybjlTVUZPT0ViSEVzZE50d3Voalg2V0Y4TG9MZVJ2WTE2dG8zeXVESTJZUjR3clFIQnJVT2NFQm9KeXp6RXN4N1dxUU11VGdfVlVEaGJR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Tango Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOT3ptQXRrMDBuQWVCUG8ya193b3Bxa0tJdkdhbDVfdGVEY0xyd1NKWk5NVGpOMC1kLUt3Ynh6OGlaclBIazczTDhLVDBMWUE2VWdvR1V1eVUzMWZUVGloMHptYUJmMjF1RF9Fb1VadE5hMVg5MlY1a19oLXdkajNDZU5rejdRUnpDMENpcWhISnpFRGtwQ0txRElhekFqWkJY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Tango Therapeutics (TNGX) Run Too Far After Recent Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQVUI0VHRya1EtdklvbXdNN2RkcFlDUTZ5dllOVkN0VmtNa0JBT1VWd1hSYzZGOHgtVmFPV0ZqRGlxZS1ZRXZFWmxYMk1WNmtjeHZaX2ZoU05BSkNiQ0Z4ZWlRbW9vM0QzdGFBNksydnB0ZFhMemU0Ym1CcThpRXYybVUtaEF3eHV3eTE3dHF4aTY4RFRrM3pOWlJBbTdVR0VQeUpudjBqSQ?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNQUdmNDlRU2JUZmhKUFM4VXJZQTZtclBHZjN3bUpoaVk1SkQtYzloTWlMSEpacjJBZ2w5QnMzWFRLTndtWXR3RW1tOHhQYmNOMkx3SDczMDhuMXRSSG8wTllPb1hMVHV2bURrN0FTTENGZ3ZaSUdIMmVkaDlKZUlRR1lpNzRkdWNILTFPMUtjaEI3QjZXNzE5SEZISEsxMFNyenlvRmJGNWt5dE5TUERjRA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sale notice \u2014 TNGX (NASDAQ:TNGX) reports planned share sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPc25pS0dFRHdCdTNGVWZJYUdvZDR3U1pjd195UTNRUGFfeGpNWkdGX1o3MF9kLWNwTlNRSEhUOGRMeVRMS0dzR1ZtNHZaQVlvamFYakhDMUp6cDZzcE5YZ1dVUGlCTDBXdjlrOTdHTEhYZjExbGE5T1VZWlhZR1FKOHJMVFZveTRXeFU5eG9ySG9TdzR3MkthQUwwdEdGWUlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics stock rockets 53% on pancreatic cancer data", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNalc5YmVHbmxCbW8xWU9hNFNDRVZzTjdPUWhIb1ItamQ4T1RVTkdsdjlfcU9VMnZWbll5ZjhHZWdUNXptUzZFNExyZnRqM0NndklHUHF0R1NudVB5MkhIMm5XajBsbkFRem5NRmtHM1d2aW1BWmVfemFiU3h4QzlqOWxJZjVCbGlBcU9wMkJKMU80LVI1aDNn?oc=5", "source_name": "grafa.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOUGRYbFhqN250WTdOY2hhMTZ6eWNpdVdlaHNvSlBRaDdPSGRRRmMzWDFjNEhqS3gwdGN5ZlZEX2ljQ2RQVERBbjJRbWRmaW81dDgxbGRBVEFKaXEzb3pwajJlNUpCSy0wN184UlYtYlhqUHh3YmxvMjdnUnBaYTJsYkNQVkJBeW5Ka2k4WG1landENmdzSE9TZ1lSX281a1hMRXRVaTFHaw?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug developer Tango Therapeutics seeks $500M in stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOWEg0dUlFQ0tPV2x1OGRyZElOUl9lQ0Yxbjg0bG11NW15cGd5aGJfVXdQdjE1amloYklrNWk0c2pfN2FXRHJ2RzJGU2tLUVo3UnlnTnJSYlZ3M0FOQWtDNWtrb3VfbGI1QUxJOHpUMkQxdjhfdWZWN1JIa0syckhFSW12a295NVVwVjZFVjA1Wk9xMXZBQ21McFhyU19GNFkxS0R5UjU3eTRkcVZSUFZwVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Announces Proposed $500 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPME1xRTYyT2pnUFlDWmVUZGlRNTdnUUpoRFhVVmNlN0FPSG5mUU0zdm5kUEdRNEIzVU5xejEwSnRYZjJlQjNNQi1oNlNKVkloLVJvT0dBSThiNm9xNFFpbEt1a1RhWjcwWmxxb3NNVkhOYUtwcEpSU2JVeVFFbnBJREpBc0tTN0MtdV9pTWhJNUQ2VjhsMFJMVDRxcG9qTzJjNTRwSjdRa3JSSnlZclNVekJLQ2JvbnRNTGNhVkNiUVpYRjNvT1Z3LTNGYzNGbUYt?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Stock Hits All-Time High \u2013 Wolfe Research Calls Tango Therapeutic\u2019s Pancreatic Cancer Trial Data \u2018Groundbreaking\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPVlBIU3BabzZ1S3hDemYxUDA5QkpQQ1RlOVV5TE5KNlI1OC1RbWZULU1JOEoycS1IVXNCR3dYSGcxeHFxa3M5eFFMWURFM0pEMnVURW5GMzQ0SzFNR2JvYmxzeUFZY1VQY2htN2RINGctbHlQODdtWDJMNnlRZmZOckNQNzRsRTNBaC1uM0ExaFM4cUxLeTV3eU1R?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQ0xyb0ZZUmFPcl9DTDJhWkkyN2drelp3TF94UjN2dWowSDNIaVV6TXZTVG1TdlM5Q081QjBwOEIxVnlTbkdNZ0p2YktqNFd3bnFrU1VRdWo0WTRCejV4Q0ppNEM3Q3M0ejREZVlZRW9HdVNOT0Y0cFE3ZXhrWXp5VUpZZ1VIemtEeEJZelRMNF9GYVJJME02NEJIcDhHSUk?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNWG1aNU1FdFZaWjFrb3RGT3ZqOXotQzYyTXYyWjdJSjR1Q2lhalFxUU1FeGk0bFRGZU85OUdCSTNUTERpQ3IyZ2ZQOVJPRVFpSGZ0MEVDRUlHdXJwanQ0QXNkckRsUk1fSWdibzgyLUJFQloxU1BIV25MSlFGdkNjd1JKMFBRWEtlUW9LeDJsWTNzaEU1bFJ2cDlqaFZNV0Ffb3c?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQVS05dzA3LU1ZalVNOVhCLTZyWHpjbGU4bW5pYkFrSXFoYldUWGVkT1hxcVhuQldydUpKaV81S0s5UEVSYkVVQ19SSDBJQ1FncFd2TmxuWElYVHNQNTJTakdBek54b3ctMW81V0ZMZERqcE1DR3pQSjlNdUZ5RmFqOEk3YlBQLW5lZW4wX2dja3YxSjJLY203cndhN3ZpaHZTRGRn?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) R&D chief exercises options, sells 12,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOdFYxM0xiN1NzeGp1dVhhMHBKZ1YyS2Y5TUhkX2NfTlFKbzZ1NEdiTllGbkIzblpjSDNtM1pKUmoyWHBIcDRVaXVNa1lHS0Z5VjlTOGJSLVhCM0RWQko2TVVTbVFGR2ppRnFUdnFkaTM2bUhKV2NoanpQdkFJMXNLNjNxckQyamtaclBfQ3F1MmF3VG4wbTlzeElTM1AtOVFYUjY0clJTNzQ5MWk3ZkI3dDI5YXpmWk0?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S Multiple", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNQk9QYjEydWU3V09lRHl4V3NOSkxTY0F0MUEtSGRqdllOX2diUkg5X2l6S3BVcXUwMGduOUEzR2tyc19ZYWhJZlI2LUlrTGJOOVJNdUJrYUxsdzYwVWVKZl9YcW5rcy1pajFKUXV4ZDgzczVkQTNVaUx2SG1kQzNBWXFRQ09SZmJnUEtLeHJn?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Stock Jumps 36% to a New High. Here\u2019s What\u2019s Driving the Move", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOVUtUeEFVY1kzc0ZOWG82alIzUTVDY2g4Vlk2ZHZZbXExUDBfcUgxbThKSHYtOXNyUVZrT3YzSkMwcjJrZmtYX3loWjV3aFdLbENQVndsSmxXMmNQWVU2eVJ0WnNaTmNsTHRqR3MyaXEwV0E2a3FBelpYb2s5UkJDZEVLVmtxcjVUYmF1WXBmeFhlSEwzZVRwOVBzZExLLUFiaEtZSQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPRDlTaUJaMnE1bVJDTHhGZ0lCUV9WcEJZRzJ4TmFlZDFvbExZc01IZlViZmZNdmxGU1RhOEhBZmVDZWdrYi1QeVIybE5mTGFzNjhoUUlmYjBsaW1iWm5Md29sbWNGRlM3MU94U193WW5mQzl6SkRPTEREUmlkZklzSG9jTFl4YUdsejlJZ1UzMFlTVklqUUhDeF9sekV5UzMzclFhdEFtRWtwdVVfaTdJN2JkUDNOTWtudllVbFA3MW1pVTlybTFRcFppZG1RaUwxY2NzREx3M3FPc042UXRsUzNzM0dkUdIB6wFBVV95cUxPU1MyOVdSdlY0QjhDb3RJVmgxeHo2Wk9kWFQyQ1JsSEszbjB6cmNlajl3R1o1N3R1aE1DYU0tMmVGUkV4ZGc4OE85MnFnZC14MjNYcGNaLUJKRUNGWktNaG1nT3dqUDMyeUtYRVMwZTR0LXJXOW45bVNFZ3JqbzZlM01jV284YU1tckRVdVVZdk5mMzBLcnR5NWpaQW9yLVkxcnVpaC1XWkxVbFFEN2tIOFZrbmpYaDB2NUJEVFliQlU3NXFyQ1diVENqSnkycTQ5emQ2SWpWbjFWTFFab2hsTkVoWlk4aFpaZ0kw?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Announces $225 Million Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQM3lsSnRRSVp0MmRuUG82WUphbGRTcDdSY0VtN0dtZnlLRHhfSW9JZFIwRmRua0hZUkVfNlNMcWdrTzhqX3psMXlnZTFOZmQ4UFREU2VHY2tQOWJqOG1DakF2Z0pEdURiU0ZPMUtHaEhlNlFnNGc4dDJROGhiZnE4SXNxWm1uLTBDVjBxazhhNUFMTlpYNC1GQ1N5YjFLZjZEQ2pWWUlkLVlwbVBoWG9iRG0zLUpZT2lYQ3IxRGdDWQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Announces Pricing of $210 Million Underwritten Offering and $15 Million PIPE Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNRFdIZHNuaFhlR1dnLWdiYmplNE5Xbm5iRUhNdThya2tZcHp6dURraE84alg4MUdzWHV3MzhXWTB0NkpKaVk1RnNWbTBhczdKcklrQ2VUd1Nkc3drNlJrTk1DZ0lZQUctZ0tMRlZPRWtucXNDV3A5Y2o2aXZHNGtyQTg4RTRkSUJOQVVLblg2T1ZyS2FsRGh5M1VYdmpjckxNcmpuNldBTXNkNUxYRjQyMGtuYkxtaDgwV1J0QVZPUUxETjR1aHBxQ0IyRkdmMUZBeUdMTTY1Qk1TZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Second Quarter 2025 Earnings: Misses Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-06T07:00:00+00:00", "published_display": "06 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating", "summary": "Mizuho has increased its price target for Tango Therapeutics (NASDAQ: TNGX) to $40, up from the previous $36, while maintaining an Outperform rating. This adjustment suggests a positive outlook on the company's future performance and stock valuation.", "url": "https://www.moomoo.com/news/post/73141654/mizuho-raises-price-target-on-tango-therapeutics-to-40-from", "source_name": "Moomoo", "published_at": "2026-07-18T05:09:30", "published_display": "18 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Maintained by Mizuho -- Price Target Raised to $40.00", "summary": "Mizuho has maintained an \"Outperform\" rating for Tango Therapeutics (TNGX) and increased its price target to $40.00, reflecting optimism about the company's growth in cancer therapies. Despite the positive analyst sentiment, GuruFocus indicates that TNGX is significantly overvalu", "url": "https://www.gurufocus.com/news/8965294/tngx-maintained-by-mizuho-price-target-raised-to-4000", "source_name": "GuruFocus", "published_at": "2026-07-17T19:41:22", "published_display": "17 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho raises Tango Therapeutics stock price target on combo data", "summary": "Mizuho has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $40 from $36, maintaining an Outperform rating, based on promising new data for its drug combinations in pancreatic cancer. This comes amidst recent positive analyst revisions and a significant stock of", "url": "https://www.investing.com/news/analyst-ratings/mizuho-raises-tango-therapeutics-stock-price-target-on-combo-data-93CH-4798117", "source_name": "Investing.com", "published_at": "2026-07-17T11:40:32", "published_display": "17 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46", "summary": "J.P. Morgan has initiated coverage on Tango Therapeutics (TNGX.US) with a 'Buy' rating. The investment bank has also set a target price of $46 for the company's stock.", "url": "https://www.moomoo.com/news/post/73000102/jp-morgan-initiates-tango-therapeutics-tngxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-16T00:40:11", "published_display": "16 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYzNHX2ZxUVlmUW5TNXlwS1FTMDRTUy1IdFR5MVVqN201SUZITVFwVUFiekdxOHNDdFR3ZElBeTdpbEtZZGhKSXQyOEYwQjBTd0VjVERDWXNudTRocEJTR3Z0enJJOXZFbzRiNklzNHl2VmdfMm1jRXVuZ3VfZEpudUdxYmw1Y0FrQlE4bFhhQUdqTGM4UmpIeDh6YWx4WjBkdU53UW44VDk?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:54+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates Tango Therapeutics stock at Overweight", "summary": "JPMorgan initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with an Overweight rating and a price target of $46.00, citing progress with its lead PRMT5 inhibitor vopimetostat and promising combination trial data. The company has seen significant stock growth, streamlined", "url": "https://m.investing.com/news/analyst-ratings/jpmorgan-initiates-tango-therapeutics-stock-at-overweight-93CH-4792323?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-15T12:39:32", "published_display": "15 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.com", "summary": "JPMorgan initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with an Overweight rating and a $46.00 price target, despite the stock's significant surge and being considered overvalued by InvestingPro analysis. The firm highlighted Tango's progress with its lead PRMT5 inhi", "url": "https://ng.investing.com/news/stock-market-news/jpmorgan-initiates-tango-therapeutics-stock-at-overweight-93CH-2599958", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T12:11:19", "published_display": "15 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Initiates Coverage On JP Morgan -- Rating Set to Overweight", "summary": "JP Morgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and a price target of $46.00. Despite this positive analyst recommendation, GuruFocus indicates that TNGX is significantly overvalued by 202.9%, with a GF Value of $9.79 against a current trad", "url": "https://www.gurufocus.com/news/8959689/tngx-initiates-coverage-on-jp-morgan-rating-set-to-overweight?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T12:11:19", "published_display": "15 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Initiates Coverage on Tango Therapeutics With Overweight Rating, $46 Price Target", "summary": "JPMorgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and set a price target of $46. This positive outlook follows several recent developments for Tango Therapeutics, including its inclusion in various Russell indices. The company specializes in d", "url": "https://www.marketscreener.com/news/jpmorgan-initiates-coverage-on-tango-therapeutics-with-overweight-rating-46-price-target-ce7f5eddd080fe23", "source_name": "www.marketscreener.com", "published_at": "2026-07-15T07:25:00", "published_display": "15 Jul 2026 07:25", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Inc (TNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Tango Therapeutics Inc (TNGX), detailing its current price momentum, support and resistance levels, and performance across various technical indicators and moving averages. As of July 15, 2026, TNGX has a price momentum score of 4.21,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tngx/technical", "source_name": "TradingKey", "published_at": "2026-07-14T00:11:34", "published_display": "14 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions?", "summary": "Tango Therapeutics (TNGX) was recently reclassified into several Russell growth indices, moving out of value and microcap segments. This shift frames TNGX as a high-growth, high-risk biotechnology narrative, potentially attracting growth-oriented institutional investors. The comp", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/does-tango-therapeutics-tngx-russell-growth-shift-reveal-its", "source_name": "Simply Wall Street", "published_at": "2026-07-09T09:10:19", "published_display": "09 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 \u2014 But Analysts Still See Massive Upside", "summary": "Tango Therapeutics (TNGX) stock crashed 20% after reporting $0 revenue in Q1, missing Wall Street expectations. Despite this, several analysts like Leerink, Mizuho, and Wedbush raised their price targets and maintained \"Outperform\" ratings, citing factors like upcoming pancreatic", "url": "https://stocktwits.com/news-articles/markets/equity/tngx-stock-worst-day-19-months-after-0-revenue-q1-price-target-double/cZXmP6LRek5", "source_name": "Stocktwits", "published_at": "2026-07-07T10:43:54", "published_display": "07 Jul 2026 10:43", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tango Therapeutics (TNGX) Fully Valued On Russell Index Rebalancing?", "summary": "Tango Therapeutics (TNGX) has experienced significant share price growth, up 48.07% over the past month and 235.27% year-to-date, due to its inclusion in Russell growth benchmarks. Despite a high Price-to-Book multiple of 11.1x, suggesting overvaluation compared to the industry a", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/is-tango-therapeutics-tngx-fully-valued-on-russell-index-reb", "source_name": "Simply Wall Street", "published_at": "2026-07-07T09:43:54", "published_display": "07 Jul 2026 09:43", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics president Crystal Adam sells $798,908 in stock", "summary": "Crystal Adam, President of Research & Development at Tango Therapeutics, sold 27,000 shares of company common stock for $798,908 after exercising stock options. The transactions were conducted under a pre-arranged trading plan, with shares sold in two blocks at weighted average p", "url": "https://www.investing.com/news/insider-trading-news/tango-therapeutics-president-crystal-adam-sells-798908-in-stock-93CH-4774754", "source_name": "Investing.com", "published_at": "2026-07-03T08:39:38", "published_display": "03 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tango Therapeutics Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing by Tango Therapeutics Inc., dated July 2. The filing indicates insider trading activity for the company, symbolized as TNGX, which saw a 1.63% increase. The brief announcement provides no further details about the nature of the transaction.", "url": "https://ng.investing.com/news/stock-market-news/form-4-tango-therapeutics-inc-for-2-july-93CH-2585450", "source_name": "Investing.com Nigeria", "published_at": "2026-07-03T00:36:00", "published_display": "03 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares", "summary": "Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised stock options for 27,000 shares at $5.20 per share and subsequently sold all 27,000 shares in open-market transactions. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred at weighte", "url": "https://www.stocktitan.net/sec-filings/TNGX/form-4-tango-therapeutics-inc-insider-trading-activity-f966c52e540d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:40:08", "published_display": "02 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tango Therapeutics, Inc. \u2013 NASDAQ:TNGX", "summary": "This article focuses on the \"Price to book forward\" metric for Tango Therapeutics, Inc. (NASDAQ:TNGX). It appears to be a financial data snippet from TradingView, providing an overview of the company's financial information within their platform. The content primarily shows the n", "url": "https://www.tradingview.com/symbols/NASDAQ-TNGX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T22:40:08", "published_display": "02 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Rides a New Precision Oncology Trend in 2026", "summary": "Tango Therapeutics is a key player in precision oncology, focusing on MTAP-deleted cancers with therapies like vopimetostat (TNG462) and TNG456. The company is using a synthetic-lethality approach and combination therapies, particularly for pancreatic, lung, and brain tumors, and", "url": "https://sg.finance.yahoo.com/news/tango-therapeutics-rides-precision-oncology-145000365.html", "source_name": "Market source", "published_at": "2026-07-02T14:50:00", "published_display": "02 Jul 2026 14:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?", "summary": "Tango Therapeutics (TNGX) has seen a dramatic rally in 2026 due to promising clinical progress with its drug vopimetostat, particularly for MTAP-deleted, RAS-mutant pancreatic cancer. Despite this, the company faces risks as it is still clinical-stage with no product revenues and", "url": "https://www.tradingview.com/news/zacks:87a242557094b:0-is-tngx-stock-still-worth-buying-after-its-huge-rally-in-2026/", "source_name": "TradingView", "published_at": "2026-07-02T14:39:59", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts", "summary": "Tango Therapeutics (TNGX) is entering a crucial period, with its stock outlook primarily tied to the success of vopimetostat and key clinical updates expected in 2026. The company's strategy focuses on MTAP-deleted cancers with a narrowed pipeline, leading to higher concentration", "url": "https://www.tradingview.com/news/zacks:59da0a0ee094b:0-tngx-stock-outlook-hinges-on-vopimetostat-and-key-2026-catalysts/", "source_name": "TradingView", "published_at": "2026-07-02T14:39:59", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Enters Russell Growth Indexes and Adds Biopharma Veteran Azelby to Board", "summary": "Tango Therapeutics (TNGX) has been included in several Russell Growth benchmarks and simultaneously removed from Value and Microcap indexes in late June 2026, signaling a market perception shift towards it as a high-growth, high-risk biotech. Concurrently, the company appointed b", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-enters-russell-growth-indexes-and-ad", "source_name": "Simply Wall Street", "published_at": "2026-07-01T05:40:41", "published_display": "01 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. This news comes alongside other index adjustments for the company, including being dropped from several ", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-added-to-russell-2500-growth-benchmark-ce7f5fdfdd89fe22", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:39:24", "published_display": "29 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 2000 Growth Benchmark. This news comes alongside several other announcements regarding the company's inclusion and exclusion from various Russell indices, including being dropped from the Russell Small Cap Co", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-added-to-russell-2000-growth-benchmark-ce7f5fded188f12c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:12:16", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM:TNGX) has been removed from the Russell Small Cap Comp Value Benchmark. This decision by S&P Capital IQ was announced on June 29, 2026, at 06:16 am EDT. Concurrently, the company was also added to the Russell 2000 Growth Benchmark and Russell 30", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8aff27", "source_name": "marketscreener.com", "published_at": "2026-06-29T10:12:16", "published_display": "29 Jun 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000 Growth Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 3000 Growth Benchmark, as announced on June 28, 2026. This inclusion is part of several recent index adjustments, which also saw the company added to the Russell 2500 Growth Benchmark and dropped from other b", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-added-to-russell-3000-growth-benchmark-ce7f5fdcd188f421", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:10:24", "published_display": "29 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Could Be 64% Below Fair Value As It Adds Robert Azelby", "summary": "Tango Therapeutics (TNGX) recently appointed Robert Azelby to its Board of Directors, as it advances its investigational PRMT5 inhibitor vopimetostat. The company's share price has shown strong momentum, with significant returns over the last year. Simply Wall St's DCF model esti", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-could-be-64-below-fair-value-as-it-a", "source_name": "Simply Wall Street", "published_at": "2026-06-29T06:39:25", "published_display": "29 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark", "summary": "Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been removed from the Russell 2500 Value Benchmark, as reported by S&P Capital IQ on June 28, 2026. This exclusion is part of several benchmark adjustments for the company around the same date, including additions to growth benchmarks", "url": "https://www.marketscreener.com/news/tango-therapeutics-inc-nasdaqgm-tngx-dropped-from-russell-2500-value-benchmark-ce7f5fded880f222", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T21:10:00", "published_display": "28 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Upgrades Tango Therapeutics to Buy From Hold, Price Target is $27", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jefferies-upgrades-tango-therapeutics-buy-111313317.html", "source_name": "MT Newswires", "published_at": "2026-06-26T11:13:13+00:00", "published_display": "26 Jun 2026 11:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Tango Therapeutics (TNGX) receives RSUs and stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxORFRYRUIwRUlRQkxoSmljd08tbGIxb3d0M1ZaQ1NLSHgtUmJlYUF0RW1fcGFSODlPYWdQV0xma3ZKbGFYVWZSQjVEeEdzWmtBVWxSbmc5ZGZyaE5jV0pUdW9rdWxNZGxSb0hsdTlTZ3Y4SGdXMHFtRnN0LVBDak4xODBtMnlRbzdsaWtYWi04N0QxQmUzMHZMNWNfelc5dzUxVENSQjZVT2xNdXN3X0NYODFtV3Ruc1k?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Appoints Robert Azelby to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/tango-therapeutics-appoints-robert-azelby-200500260.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T20:05:00+00:00", "published_display": "22 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX (Nasdaq: TNGX) affiliate files Form 144 to sell 3.5M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRVdPWDdVNlh3RVBnM2dmbjBLWlVxRXJYeWQtbFh3ZUJtUmpwRk5rQndGN0hPZEM1SVNzeTJVLXhyTEliYTRtYlNuZ0pKNWdtZmcybjlTVUZPT0ViSEVzZE50d3Voalg2V0Y4TG9MZVJ2WTE2dG8zeXVESTJZUjR3clFIQnJVT2NFQm9KeXp6RXN4N1dxUU11VGdfVlVEaGJR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Tango Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOT3ptQXRrMDBuQWVCUG8ya193b3Bxa0tJdkdhbDVfdGVEY0xyd1NKWk5NVGpOMC1kLUt3Ynh6OGlaclBIazczTDhLVDBMWUE2VWdvR1V1eVUzMWZUVGloMHptYUJmMjF1RF9Fb1VadE5hMVg5MlY1a19oLXdkajNDZU5rejdRUnpDMENpcWhISnpFRGtwQ0txRElhekFqWkJY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Tango Therapeutics (TNGX) Run Too Far After Recent Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQVUI0VHRya1EtdklvbXdNN2RkcFlDUTZ5dllOVkN0VmtNa0JBT1VWd1hSYzZGOHgtVmFPV0ZqRGlxZS1ZRXZFWmxYMk1WNmtjeHZaX2ZoU05BSkNiQ0Z4ZWlRbW9vM0QzdGFBNksydnB0ZFhMemU0Ym1CcThpRXYybVUtaEF3eHV3eTE3dHF4aTY4RFRrM3pOWlJBbTdVR0VQeUpudjBqSQ?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNQUdmNDlRU2JUZmhKUFM4VXJZQTZtclBHZjN3bUpoaVk1SkQtYzloTWlMSEpacjJBZ2w5QnMzWFRLTndtWXR3RW1tOHhQYmNOMkx3SDczMDhuMXRSSG8wTllPb1hMVHV2bURrN0FTTENGZ3ZaSUdIMmVkaDlKZUlRR1lpNzRkdWNILTFPMUtjaEI3QjZXNzE5SEZISEsxMFNyenlvRmJGNWt5dE5TUERjRA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sale notice \u2014 TNGX (NASDAQ:TNGX) reports planned share sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPc25pS0dFRHdCdTNGVWZJYUdvZDR3U1pjd195UTNRUGFfeGpNWkdGX1o3MF9kLWNwTlNRSEhUOGRMeVRMS0dzR1ZtNHZaQVlvamFYakhDMUp6cDZzcE5YZ1dVUGlCTDBXdjlrOTdHTEhYZjExbGE5T1VZWlhZR1FKOHJMVFZveTRXeFU5eG9ySG9TdzR3MkthQUwwdEdGWUlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics stock rockets 53% on pancreatic cancer data", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNalc5YmVHbmxCbW8xWU9hNFNDRVZzTjdPUWhIb1ItamQ4T1RVTkdsdjlfcU9VMnZWbll5ZjhHZWdUNXptUzZFNExyZnRqM0NndklHUHF0R1NudVB5MkhIMm5XajBsbkFRem5NRmtHM1d2aW1BWmVfemFiU3h4QzlqOWxJZjVCbGlBcU9wMkJKMU80LVI1aDNn?oc=5", "source_name": "grafa.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOUGRYbFhqN250WTdOY2hhMTZ6eWNpdVdlaHNvSlBRaDdPSGRRRmMzWDFjNEhqS3gwdGN5ZlZEX2ljQ2RQVERBbjJRbWRmaW81dDgxbGRBVEFKaXEzb3pwajJlNUpCSy0wN184UlYtYlhqUHh3YmxvMjdnUnBaYTJsYkNQVkJBeW5Ka2k4WG1landENmdzSE9TZ1lSX281a1hMRXRVaTFHaw?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug developer Tango Therapeutics seeks $500M in stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOWEg0dUlFQ0tPV2x1OGRyZElOUl9lQ0Yxbjg0bG11NW15cGd5aGJfVXdQdjE1amloYklrNWk0c2pfN2FXRHJ2RzJGU2tLUVo3UnlnTnJSYlZ3M0FOQWtDNWtrb3VfbGI1QUxJOHpUMkQxdjhfdWZWN1JIa0syckhFSW12a295NVVwVjZFVjA1Wk9xMXZBQ21McFhyU19GNFkxS0R5UjU3eTRkcVZSUFZwVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Announces Proposed $500 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPME1xRTYyT2pnUFlDWmVUZGlRNTdnUUpoRFhVVmNlN0FPSG5mUU0zdm5kUEdRNEIzVU5xejEwSnRYZjJlQjNNQi1oNlNKVkloLVJvT0dBSThiNm9xNFFpbEt1a1RhWjcwWmxxb3NNVkhOYUtwcEpSU2JVeVFFbnBJREpBc0tTN0MtdV9pTWhJNUQ2VjhsMFJMVDRxcG9qTzJjNTRwSjdRa3JSSnlZclNVekJLQ2JvbnRNTGNhVkNiUVpYRjNvT1Z3LTNGYzNGbUYt?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TNGX Stock Hits All-Time High \u2013 Wolfe Research Calls Tango Therapeutic\u2019s Pancreatic Cancer Trial Data \u2018Groundbreaking\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPVlBIU3BabzZ1S3hDemYxUDA5QkpQQ1RlOVV5TE5KNlI1OC1RbWZULU1JOEoycS1IVXNCR3dYSGcxeHFxa3M5eFFMWURFM0pEMnVURW5GMzQ0SzFNR2JvYmxzeUFZY1VQY2htN2RINGctbHlQODdtWDJMNnlRZmZOckNQNzRsRTNBaC1uM0ExaFM4cUxLeTV3eU1R?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQ0xyb0ZZUmFPcl9DTDJhWkkyN2drelp3TF94UjN2dWowSDNIaVV6TXZTVG1TdlM5Q081QjBwOEIxVnlTbkdNZ0p2YktqNFd3bnFrU1VRdWo0WTRCejV4Q0ppNEM3Q3M0ejREZVlZRW9HdVNOT0Y0cFE3ZXhrWXp5VUpZZ1VIemtEeEJZelRMNF9GYVJJME02NEJIcDhHSUk?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNWG1aNU1FdFZaWjFrb3RGT3ZqOXotQzYyTXYyWjdJSjR1Q2lhalFxUU1FeGk0bFRGZU85OUdCSTNUTERpQ3IyZ2ZQOVJPRVFpSGZ0MEVDRUlHdXJwanQ0QXNkckRsUk1fSWdibzgyLUJFQloxU1BIV25MSlFGdkNjd1JKMFBRWEtlUW9LeDJsWTNzaEU1bFJ2cDlqaFZNV0Ffb3c?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQVS05dzA3LU1ZalVNOVhCLTZyWHpjbGU4bW5pYkFrSXFoYldUWGVkT1hxcVhuQldydUpKaV81S0s5UEVSYkVVQ19SSDBJQ1FncFd2TmxuWElYVHNQNTJTakdBek54b3ctMW81V0ZMZERqcE1DR3pQSjlNdUZ5RmFqOEk3YlBQLW5lZW4wX2dja3YxSjJLY203cndhN3ZpaHZTRGRn?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) R&D chief exercises options, sells 12,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOdFYxM0xiN1NzeGp1dVhhMHBKZ1YyS2Y5TUhkX2NfTlFKbzZ1NEdiTllGbkIzblpjSDNtM1pKUmoyWHBIcDRVaXVNa1lHS0Z5VjlTOGJSLVhCM0RWQko2TVVTbVFGR2ppRnFUdnFkaTM2bUhKV2NoanpQdkFJMXNLNjNxckQyamtaclBfQ3F1MmF3VG4wbTlzeElTM1AtOVFYUjY0clJTNzQ5MWk3ZkI3dDI5YXpmWk0?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S Multiple", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNQk9QYjEydWU3V09lRHl4V3NOSkxTY0F0MUEtSGRqdllOX2diUkg5X2l6S3BVcXUwMGduOUEzR2tyc19ZYWhJZlI2LUlrTGJOOVJNdUJrYUxsdzYwVWVKZl9YcW5rcy1pajFKUXV4ZDgzczVkQTNVaUx2SG1kQzNBWXFRQ09SZmJnUEtLeHJn?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Stock Jumps 36% to a New High. Here\u2019s What\u2019s Driving the Move", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOVUtUeEFVY1kzc0ZOWG82alIzUTVDY2g4Vlk2ZHZZbXExUDBfcUgxbThKSHYtOXNyUVZrT3YzSkMwcjJrZmtYX3loWjV3aFdLbENQVndsSmxXMmNQWVU2eVJ0WnNaTmNsTHRqR3MyaXEwV0E2a3FBelpYb2s5UkJDZEVLVmtxcjVUYmF1WXBmeFhlSEwzZVRwOVBzZExLLUFiaEtZSQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Announces $225 Million Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQM3lsSnRRSVp0MmRuUG82WUphbGRTcDdSY0VtN0dtZnlLRHhfSW9JZFIwRmRua0hZUkVfNlNMcWdrTzhqX3psMXlnZTFOZmQ4UFREU2VHY2tQOWJqOG1DakF2Z0pEdURiU0ZPMUtHaEhlNlFnNGc4dDJROGhiZnE4SXNxWm1uLTBDVjBxazhhNUFMTlpYNC1GQ1N5YjFLZjZEQ2pWWUlkLVlwbVBoWG9iRG0zLUpZT2lYQ3IxRGdDWQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Announces Pricing of $210 Million Underwritten Offering and $15 Million PIPE Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNRFdIZHNuaFhlR1dnLWdiYmplNE5Xbm5iRUhNdThya2tZcHp6dURraE84alg4MUdzWHV3MzhXWTB0NkpKaVk1RnNWbTBhczdKcklrQ2VUd1Nkc3drNlJrTk1DZ0lZQUctZ0tMRlZPRWtucXNDV3A5Y2o2aXZHNGtyQTg4RTRkSUJOQVVLblg2T1ZyS2FsRGh5M1VYdmpjckxNcmpuNldBTXNkNUxYRjQyMGtuYkxtaDgwV1J0QVZPUUxETjR1aHBxQ0IyRkdmMUZBeUdMTTY1Qk1TZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tango Therapeutics Second Quarter 2025 Earnings: Misses Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-06T07:00:00+00:00", "published_display": "06 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 59, "sentiment_summary": {"positive": 21, "negative": 5, "neutral": 33, "score": 56, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 20.35, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 4.95, "count": 9}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 28.56, "latest_week": "2026-07-17", "one_week_move": -8.0, "four_week_move": 2.1, "twelve_week_move": 10.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.445493, "market_dynamics_buy_signal": false, "relative_strength": 80.548755, "fair_value_gap": 206.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.5517, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.0% over one week, +2.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "Stock Titan", "count": 8}, {"label": "www.marketscreener.com", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Simply Wall Street", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 9}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-8.0% over one week, +2.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating"}], "updated_at": "2026-07-19T17:46:35.355021+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}